Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Dr. Rudolf  Ertl

Senior Vice President of Commercial Operations of Australia, Canada, Europe

Ms. Jacquie  Ross C.F.A.

Vice President of Investor Relations

Dr. Linda Slanec Higgins Ph.D.

Senior Vice President of Research, Innovation & Portfolio

Ms. Deborah H. Telman

Executive Vice President of Corporate Affairs, General Counsel & Corporate Secretary

Ms. Johanna  Mercier

Chief Commercial Officer

Ms. Sandra  Patterson

Senior Vice President, Corporate Controller & Principal Accounting Officer

Ms. Jyoti K. Mehra

Executive Vice President of Human Resources

Mr. Andrew D. Dickinson

Chief Financial Officer

Mr. Daniel P.  O'Day

Chairman & Chief Executive Officer

Dr. Merdad V. Parsey M.D., Ph.D.

Chief Medical Officer

Nazwa	Kapitalizacja rynkowa
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.	0M
Marksans Pharma Limited	0M
Luye Pharma Group Ltd.	0M
PT Kalbe Farma Tbk.	0M
Virbac SA	0M
Daiichi Sankyo Company, Limited	0M
Astellas Pharma Inc.	0M
Orion Oyj	0M
Amgen Inc.	0M
Novartis AG	0M
Chugai Pharmaceutical Co., Ltd.	0M

Gilead Sciences, Inc.

Gilead Sciences, Inc. Lista konkurentów

Główni konkurenci